Pharsight

Drug Patents Expiring in 2017

1. Descovy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5914331 GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-285) Sep 28, 2024
Orphan Drug Exclusivity(ODE-284) Sep 28, 2024
Orphan Drug Exclusivity(ODE-457) Jan 07, 2029
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Patient Population(NPP) Sep 28, 2020
New Indication(I-812) Oct 03, 2022

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 07 January, 2022

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

2. Duavee patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7138392 WYETH PHARMS 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
Apr, 2017

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 13, 2018
New Product(NP) Oct 03, 2016

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

NCE-1 date: 13 October, 2017

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis

Dosage: TABLET;ORAL

More Information on Dosage

DUAVEE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Evotaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5849911 BRISTOL Antivirally active heterocyclic azahexane derivatives
Jun, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: Method for treating hiv-1 infection

Dosage: TABLET;ORAL

How can I launch a generic of EVOTAZ before it's drug patent expiration?
More Information on Dosage

EVOTAZ family patents

Family Patents

4. Genvoya patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5914331 GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Dosing Schedule(D-173) Dec 10, 2021
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

5. Iressa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5770599 ASTRAZENECA Quinazoline derivatives
May, 2017

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 13, 2022
New Product(NP) Jul 13, 2018
Orphan Drug Exclusivity(ODE-95) Jul 13, 2022

Drugs and Companies using GEFITINIB ingredient

Market Authorisation Date: 13 July, 2015

Treatment: First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutation...

Dosage: TABLET;ORAL

More Information on Dosage

IRESSA family patents

Family Patents

6. Jadenu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6596750 NOVARTIS PHARMS CORP Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Jun, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-241) Jul 24, 2022
Orphan Drug Exclusivity(ODE) Jan 23, 2020
M(M-239) Dec 12, 2021
Orphan Drug Exclusivity(ODE-39) Jan 23, 2020
M(M-263) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 30 March, 2015

Treatment: Method of treating chronic iron overload

Dosage: TABLET;ORAL

How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage

JADENU family patents

Family Patents

7. Odefsey patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5914331 GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-207) Aug 21, 2020
M(M-206) Aug 21, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

8. Orbactiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5998581 MELINTA THERAP Reductive alkylation of glycopeptide antibiotics
Nov, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 06, 2019
Generating Antibiotic Incentives Now(GAIN) Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ORBACTIV family patents

Family Patents

9. Orenitram patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6765117 UNITED THERAP Process for stereoselective synthesis of prostacyclin derivatives
Oct, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-272) Oct 18, 2026
New Dosage Form(NDF) Dec 20, 2016
New Indication(I-820) Oct 18, 2022
New Dosing Schedule(D-156) Jan 28, 2019
New Dosing Schedule(D-157) Jan 28, 2019
Orphan Drug Exclusivity(ODE-308) Dec 20, 2020

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage

ORENITRAM family patents

Family Patents

10. Prezcobix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43596 JANSSEN PRODS α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
May, 2017

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PREZCOBIX before it's drug patent expiration?
More Information on Dosage

PREZCOBIX family patents

Family Patents

11. Reyataz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5849911 BRISTOL MYERS SQUIBB Antivirally active heterocyclic azahexane derivatives
Jun, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 02, 2017
New Patient Population(NPP) Sep 24, 2018
Pediatric Exclusivity(PED) Mar 24, 2019

Drugs and Companies using ATAZANAVIR SULFATE ingredient

Market Authorisation Date: 02 June, 2014

Treatment: Method for treating hiv-1 infection

Dosage: POWDER;ORAL

How can I launch a generic of REYATAZ before it's drug patent expiration?
More Information on Dosage

REYATAZ family patents

Family Patents

12. Saxenda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6458924 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US7235627 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 04, 2023
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

13. Somavert patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5849535 PHARMACIA Human growth hormone variants
Mar, 2017

(7 years ago)

Drugs and Companies using PEGVISOMANT ingredient

Market Authorisation Date: 31 July, 2014

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

SOMAVERT family patents

Family Patents

14. Spinraza patents expiration

Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6166197 BIOGEN IDEC Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
Dec, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-226) May 14, 2021
Orphan Drug Exclusivity(ODE-127) Dec 23, 2023
New Chemical Entity Exclusivity(NCE) Dec 23, 2021
Orphan Drug Exclusivity(ODE) Dec 23, 2023

Drugs and Companies using NUSINERSEN SODIUM ingredient

NCE-1 date: 23 December, 2020

Market Authorisation Date: 23 December, 2016

Treatment: NA

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

SPINRAZA family patents

Family Patents

15. Truvada patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5914331 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

US5977089 GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5922695 GILEAD Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jul, 2017

(6 years ago)

US5935946 GILEAD Nucleotide analog composition and synthesis method
Jul, 2017

(6 years ago)

Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: Method of treatment of adults infected with hiv-1; Prophylaxis of hiv-1 infection; Treatment of hiv

Dosage: TABLET;ORAL

How can I launch a generic of TRUVADA before it's drug patent expiration?
More Information on Dosage

TRUVADA family patents

Family Patents

16. Xtoro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6432948 FONSECA BIOSCIENCES Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases
Apr, 2017

(7 years ago)

US6133260 FONSECA BIOSCIENCES Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases
Apr, 2017

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 17, 2019
Pediatric Exclusivity(PED) Jun 17, 2020

Drugs and Companies using FINAFLOXACIN ingredient

NCE-1 date: 18 June, 2019

Market Authorisation Date: 17 December, 2014

Treatment: NA

Dosage: SUSPENSION/DROPS;OTIC

More Information on Dosage

XTORO family patents

Family Patents

17. Xultophy 100/3.6 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6458924 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US7235627 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-242) Aug 08, 2022
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

XULTOPHY 100/3.6 family patents

Family Patents

List of large molecules

1. List of Tysabri large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US5840299 NA Humanized antibodies against leukocyte adhesion molecule VLA-4
Apr, 2017

(7 years ago)

Ingredients: NATALIZUMAB